trending Market Intelligence /marketintelligence/en/news-insights/trending/fZlMLnpdwx3T6SyBC8fQ1A2 content esgSubNav
In This List

NICE approves use of Merck's Keytruda under cancer fund

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


NICE approves use of Merck's Keytruda under cancer fund

The U.K.'s National Institute for Health and Care Excellence cleared the use of Merck & Co. Inc.'s cancer drug Keytruda in previously untreated lung cancer patients under funding arrangements within the Cancer Drugs Fund, Reuters reported.

The agency did not recommend the routine use of the drug for newly diagnosed patients due to its high cost and uncertainties about overall survival benefits.